



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

## Adalimumab (anti-TNF- $\alpha$ )

Cat. No.:	HY-P9908A
CAS No.:	331731-18-1
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Adalimumab (anti-TNF- $\alpha$ ) is a human monoclonal IgG1 antibody targeting tumour necrosis factor $\alpha$ (TNF- $\alpha$ ).
<b>In Vitro</b>	Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab (anti-TNF- $\alpha$ ) than used in this study <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	The elimination half-life ( $t_{1/2}$ ) of Adalimumab (anti-TNF- $\alpha$ ) is long (~20 days) <sup>[1]</sup> . The enriched fluorescent-labelled adalimumab (anti-TNF- $\alpha$ ) is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr <sup>-/-</sup> mice <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. *Br J Clin Pharmacol*. 2015 Feb;79(2):286-97.
- [2]. Oberoi R, et al. Targeting Tumor Necrosis Factor- $\alpha$  with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. *PLoS One*. 2016 Jul 28;11(7):e0160145.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA